Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

References

• WeiXGhoshSKTaylorMEViral dynamics in human immunodeficiency virus type 1 infectionNature199537365101171227529365
   PubMed Web of Science ®Google Scholar
• BrassALDykxhoornDMBenitaYIdentification of host proteins required for HIV infection through a functional genomic screenScience2008319586592192618187620
   PubMed Web of Science ®Google Scholar
• WilliamsIChurchillDAndersonJBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012HIV Med201213Suppl 2185
   Google Scholar
• KhatibNDasSPRO 140 – a novel CCR5 co-receptor inhibitorRecent Pat Antiinfect Drug Discov201051182219807678
   PubMedGoogle Scholar
• DasSLipid Disorder in HIV Infection: Apolipoprotein-B Kinetics, Fat Distribution, Insulin Resistance and Adipocytokines in Patients Taking Protease Inhibitors or Non-Nucleoside Reverse Transcriptase InhibitorsUniversity of Birmingham2010 Available from: http://etheses.bham.ac.uk/1475/
   Google Scholar
• Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?MMW Fortschr Med2014156Suppl 15859
   Google Scholar
• ArribasJREronJAdvances in antiretroviral therapyCurr Opin HIV AIDS20138434134923666392
   PubMed Web of Science ®Google Scholar
• AdamsJLGreenerBNKashubaADPharmacology of HIV integrase inhibitorsCurr Opin HIV AIDS20127539040022789987
   PubMed Web of Science ®Google Scholar
• TahaHMorganJDasADasSParenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infectionRecent Pat Antiinfect Drug Discov20138321321824738551
   PubMedGoogle Scholar
• KohYWuXFerrisALDifferential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integrationJ Virol201387164865823097450
   PubMed Web of Science ®Google Scholar
• CottrellMLHadzicTKashubaADClinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravirClin Pharmacokinet2013521198199423824675
   PubMed Web of Science ®Google Scholar
• HareSSmithSJMetifiotMStructural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)Mol Pharmacol201180456557221719464
   PubMed Web of Science ®Google Scholar
• AdamsJLPattersonKBPrinceHMSingle and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative womenAntivir Ther20141881005101323899439
   PubMed Web of Science ®Google Scholar
• SongIBorlandJChenSEffect of food on the pharmacokinetics of the integrase inhibitor dolutegravirAntimicrob Agents Chemother20125631627162922183173
   PubMed Web of Science ®Google Scholar
• CastellinoSMossLWagnerDMetabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humansAntimicrob Agents Chemother20135783536354623669385
   PubMed Web of Science ®Google Scholar
• DeAndaFHightowerKENolteRTDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsPLoS One2013810e7744824146996
   PubMed Web of Science ®Google Scholar
• ChenSSt JeanPBorlandJEvaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokineticsPharmacogenomics201415191624329186
   PubMed Web of Science ®Google Scholar
• GutierrezFFulladosaXBarrilGDomingoPRenal tubular transporter-mediated interactions of HIV drugs: implications for patient managementAIDS Rev201416419921225350530
   PubMed Web of Science ®Google Scholar
• LepistEIZhangXHaoJContribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistatKidney Int201486235035724646860
   PubMed Web of Science ®Google Scholar
• KoteffJBorlandJChenSA phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjectsBr J Clin Pharmacol201375499099622905856
   PubMed Web of Science ®Google Scholar
• PatelPSongIBorlandJPharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteersJ Antimicrob Chemother20116671567157221493648
   PubMed Web of Science ®Google Scholar
• CrauwelsHvan HeeswijkRPStevensMClinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirineAIDS Rev20131528710123681436
   PubMed Web of Science ®Google Scholar
• SongIBorlandJChenSEffects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravirEur J Clin Pharmacol201470101173117925146692
   PubMed Web of Science ®Google Scholar
• SongIBorlandJMinSEffects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravirAntimicrob Agents Chemother20115573517352121555764
   PubMed Web of Science ®Google Scholar
• FordSLGouldEChenSLack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744Antimicrob Agents Chemother201357115472547723979733
   PubMed Web of Science ®Google Scholar
• SongIMinSSBorlandJThe effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participantsJ Clin Pharmacol201151223724220489027
   PubMed Web of Science ®Google Scholar
• SongIBorlandJChenSEffect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572Br J Clin Pharmacol201172110310821342217
   PubMed Web of Science ®Google Scholar
• SongIBorlandJAryaNWynneBPiscitelliSPharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjectsJ Clin Pharmacol201455549049625449994
   PubMed Web of Science ®Google Scholar
• DooleyKESayrePBorlandJSafety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjectsJ Acquir Immune Defic Syndr2013621212723075918
   PubMed Web of Science ®Google Scholar
• JohnsonMBorlandJChenSSavinaPWynneBPiscitelliSEffects of boceprevir and telaprevir on the pharmacokinetics of dolutegravirBr J Clin Pharmacol20147851043104924838177
   PubMed Web of Science ®Google Scholar
• YehWFengH-PGuoZDrug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravirConference on Retrovirus and Opportunistic Infection2015Seattle, USA
   Google Scholar
• SongIHBorlandJChenSWajimaTPeppercornAFPiscitelliSCDolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiolAnn Pharmacother201549778478925862012
   PubMed Web of Science ®Google Scholar
• DrewBJAckermanMJFunkMPrevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology FoundationJ Am Coll Cardiol201055993494720185054
   PubMed Web of Science ®Google Scholar
• MinSSongIBorlandJPharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteersAntimicrob Agents Chemother201054125425819884365
   PubMed Web of Science ®Google Scholar
• GilletteMAShahBMSchaferJJDeSimoneJAJrDolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV – an alternative viewpointPharmacotherapy2014349e173e17425182330
   PubMed Web of Science ®Google Scholar
• ReeseMJSavinaPMGenerauxGTIn vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorDrug Metab Dispos201341235336123132334
   PubMed Web of Science ®Google Scholar
• ZongJBorlandJJervaFWynneBChoukourMSongIThe effect of dolutegravir on the pharmacokinetics of metformin in healthy subjectsJ Int AIDS Soc2014174 Suppl 31958425394090
   PubMed Web of Science ®Google Scholar
• SongIHBorlandJChenSSavinaPPeppercornAFPiscitelliSEffect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravirAntimicrob Agents Chemother20135794394439723817375
   PubMed Web of Science ®Google Scholar
• InformationDDolutegravir Tablet2015 Available from: http://www.druginformation.com/RxDrugs/D/Dolutegravir%20Tablets.html
   Google Scholar
• SongIMarkSChenSDolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjectsDrug Alcohol Depend2013133278178424018316
   PubMed Web of Science ®Google Scholar
• van LunzenJMaggioloFArribasJROnce daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialLancet Infect Dis201212211111822018760
   PubMed Web of Science ®Google Scholar
• WalmsleySLAntelaAClumeckNDolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionN Engl J Med2013369191807181824195548
   PubMed Web of Science ®Google Scholar
• RaffiFRachlisABrinsonCDolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trialsAIDS201529216717425387312
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanEOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialLancet Infect Dis2013131192793524074642
   PubMed Web of Science ®Google Scholar
• ClotetBFeinbergJvan LunzenJOnce-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyLancet201438399362222223124698485
   PubMed Web of Science ®Google Scholar
• CahnPPozniakALMingroneHDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyLancet2013382989370070823830355
   PubMed Web of Science ®Google Scholar
• EronJJClotetBDurantJSafety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING studyJ Infect Dis2013207574074823225901
   PubMed Web of Science ®Google Scholar
• CastagnaAMaggioloFPencoGDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyJ Infect Dis2014210335436224446523
   PubMed Web of Science ®Google Scholar
• AkilBBlickGHaginsDPDolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized studyAntivir Ther201520334334825321146
   PubMed Web of Science ®Google Scholar
• OliveiraMMespledeTQuashiePKMoisiDWainbergMAResistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitorsAIDS201428681381924463394
   PubMed Web of Science ®Google Scholar
• GranierCGivensNCuffeRConsistency of dolutegravir treatment difference in HIV+ treatment naives at week 96Conference on Retrovirus and Opportunistic Infection2015Seattle, USA
   Google Scholar
• ArmeniaDFabeniLAlteriCHIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemiaJ Antimicrob Chemother20157061865187325712318
   PubMed Web of Science ®Google Scholar
• UnderwoodMRJohnsBASatoAThe activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adultsJ Acquir Immune Defic Syndr201261329730122878423
   PubMed Web of Science ®Google Scholar
• BessongPONwobegahayJGenetic analysis of HIV-1 integrase sequences from treatment naive individuals in Northeastern South AfricaInt J Mol Sci20131435013502423455469
   PubMed Web of Science ®Google Scholar
• BastaracheSMMespledeTDonahueDASloanRDWainbergMAFitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latencyViruses2014693487349925243372
   PubMed Web of Science ®Google Scholar
• BlakeMSoniaVDolutegravir: a new HIV integrase inhibitor for the treatment of HIV infectionFuture Virol2015911967978
   Web of Science ®Google Scholar
• BoydMACooperDASPRING-2 the future of antiretroviral therapyLancet Infect Dis2013131190890924074643
   PubMed Web of Science ®Google Scholar
• McCormackPLDolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adultsDrugs201474111241125225005775
   PubMed Web of Science ®Google Scholar
• PatelDASnedecorSJTangWY48-Week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysisPLoS One201499e10565325188312
   PubMed Web of Science ®Google Scholar
• QuerciaRRobertsJMartin-CarpenterLZalaCComparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeksClin Drug Investig2015353211219
   PubMed Web of Science ®Google Scholar
• TebasPKumarPHicksC48 Week bone marker changes in dolutegravir (DTG; GSK1349572) plus abacavir/lamivudine (ABC/3TC) vs tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial53rd Interscience Conference on Antimicrobial Agents and Chemotherapy2013Denver, USA
   Google Scholar
• TebasPQuerciaQPaiceASINGLE W144: greater changes in bone turnover markers in antiretroviral therapy-naïve individuals initiating efavirenz/emtricitabine/tenofovir disoproxil fumarate compared with dolutegravir plus abacavir/lamivudinePoster presented at: 21st Annual Conference of the British HIV Association (BHIVA)April 21–24, 2015Brighton, UK
   Google Scholar
• NelsonMRMatthewsGBrookMGMainJBHIVA guidelines: coinfection with HIV and chronic hepatitis C virusHIV Med20034Suppl 1526214511248
   PubMedGoogle Scholar
• SteklerJDMcKernanJMilneRLack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013Antivir Ther2015201778024831260
   PubMed Web of Science ®Google Scholar
• FrantzellAPetropoulosCJHuangWDolutegravir resistance requires multiple primary mutations in HIV-1 integraseConference on Retrovirus and Opportunistic Infection2015Seattle, USA
   Google Scholar
• NachegaJBParientiJJUthmanOALower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trialsClin Infect Dis20145891297130724457345
   PubMed Web of Science ®Google Scholar
• WuPJohnsonBANachegaJBThe combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South AfricaCurr HIV Res201412536637525426940
   PubMed Web of Science ®Google Scholar
• Gimeno-GraciaMCrusells-CanalesMJJavier Armesto-GomezFRabanaque-HernandezMJPrevalence of concomitant medications in older HIV+ patients and comparison with general populationHIV Clin Trials201516311712425978302
   PubMed Web of Science ®Google Scholar
• PatelRMooreTCooperVAn observational study of comorbidity and healthcare utilisation among HIV-positive patients aged 50 years and overInt J STD AIDS Epub2015610
   Web of Science ®Google Scholar
• DasSRisk of cardiovascular disease in HIV-infected patientsJ Antimicrob Chemother201065338638920026610
   PubMed Web of Science ®Google Scholar
• DasSEvaluation of cardiovascular risk in HIV patients: clinical implicationInt J Clin Pract20106491173117520653794
   PubMed Web of Science ®Google Scholar
• PainJBLeMPCaserisMPharmacokinetic of dolutegravir in a premature neonate after HIV treatment intensification during pregnancyAntimicrob Agents Chemother20155963660366225845873
   PubMed Web of Science ®Google Scholar
• WellerSBorlandJChenSPharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairmentEur J Clin Pharmacol2014701293524096683
   PubMed Web of Science ®Google Scholar
• LeeFJCarrATolerability of HIV integrase inhibitorsCurr Opin HIV AIDS20127542242822886031
   PubMed Web of Science ®Google Scholar
• MillerMMLiedtkeMDLockhartSMRathbunRCThe role of dolutegravir in the management of HIV infectionInfect Drug Resist20158192925733917
   PubMed Web of Science ®Google Scholar
• SurgersLLacombeKHepatoxicity of new antiretrovirals: a systematic reviewClin Res Hepatol Gastroenterol201337212613323522569
   PubMed Web of Science ®Google Scholar